IMM News: Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer - 27th Jun 2022, 10:00pm

annb0t

Top 20
Immutep Limited

SYDNEY, AUSTRALIA, June 27, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, announces new data from second line non-small cell lung cancer patients (Part B) in the Phase II TACTI-002 trial has been selected for a poster presentation at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022) taking pla...

>>> Read more: Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer
 
Top Bottom